NCT01809275View on ClinicalTrials.gov

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

July 31, 2016

Conditions
Crohn's DiseaseInflammatory Bowel Disease
Interventions
DRUG

QBECO

DRUG

Placebo

Trial Locations (4)

T2N 4Z6

University of Calgary, Calgary

T6G 2X8

University of Alberta Zeidler Ledcor Centre, Edmonton

V6Z 2K5

GI Research Institute, Vancouver

L4L 4Y7

Toronto Digestive Disease Associates, Vaughan

All Listed Sponsors
lead

Qu Biologics Inc.

INDUSTRY

NCT01809275 - Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter